In:
Journal of Viral Hepatitis, Wiley, Vol. 26, No. S1 ( 2019-07), p. 85-89
Abstract:
The long‐term administration of nucleotide analogues (NAs) and hepatitis B immune globulin (HBIG) comprises standard prophylaxis for patients with hepatitis B virus (HBV)‐related liver diseases to prevent HBV reinfection after liver transplantation (LT). However, prolonging the prophylaxis strategy involves safety issues, such as the development of escape mutations and/or emerging resistant strains, and is also associated with high costs; further, it remains unclear how long prophylactic treatment should be continued. Method Liver transplantation recipients responding to hepatitis B vaccination due to HBV‐related liver diseases were retrospectively analysed after stopping HBIG and/or NAs, administered to prevent HBV reinfection, after long‐term follow‐up. The safety and effectiveness of the strategy were then evaluated for these responders. Result Seventy‐eight responders were enrolled. All responders discontinued HBIG, among which 36 stopped both HBIG and NAs. During follow‐up, four recipients experienced HBV reinfection, which was associated with HBV escape mutations, after the withdrawal of both HBIG and NAs. No death or graft loss occurred in recipients during the follow‐up period. Conclusion A careful withdrawal of HBIG and/or NAs is feasible and safe for responders to hepatitis B vaccination receiving transplants for HBV‐related liver diseases.
Type of Medium:
Online Resource
ISSN:
1352-0504
,
1365-2893
Language:
English
Publisher:
Wiley
Publication Date:
2019
detail.hit.zdb_id:
2007924-2
Permalink